References
- Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the Rheumatic Diseases [Internet]. 2014;73:1316–1322. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2013-204627
- Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Research & Therapy [Internet]. 2010;12:R42. [cited 2021 Apr 20]. Available from: http://arthritis-research.biomedcentral.com/articles/10.1186/ar2951
- Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Seminars in Arthritis and Rheumatism [Internet]. 2014;44:123–130. [cited 2021 Apr 20]. Available from:https://linkinghub.elsevier.com/retrieve/pii/S004901721400071
- Alamanos Y, Voulgari P, AA D. Incidence and prevalence of rheumatoid arthritis, based on the 1987 american college of rheumatology criteria: a systematic review. seminars in arthritis and rheumatism [Internet]. 2006;36:182–188. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049017206001107
- Kirkham B, Chan E, Vincent AEA REAL-Life Cost of UK healthcare resource for patients with rheumatoid arthritis, comparing high and low/remission disease states [abstract]. 2016; [cited 2021 Apr 20]. Available from: https://acrabstracts.org/abstract/real-life-cost-of-uk-healthcare-resource-for-patients-with-rheumatoid-arthritis-comparing-high-and-lowremission-disease-states/
- Vanderpoel J, Tkacz J, Brady BL, et al. Health care resource utilization and costs associated with switching biologics in rheumatoid arthritis [Clinical Therapeutics Internet]. 2019;41:1080–1089. e5. [cited 2021 Apr 20]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0149291819301997
- Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis & Rheumatism [Internet]. 2007;56:13–20. [cited 2021 Apr 20]. Available from: http://doi.wiley.com/10.1002/art.22331
- Buch MH, Defining refractory rheumatoid arthritis. Ann Rheum Dis. Internet]. 2018;77:966–969. [cited 2021 Apr 20]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2017-212862
- Manning G The protein kinase complement of the human genome. Science [Internet]. 2002;298:1912–1934. [cited 2021 Apr 20]. Available from: https://www.sciencemag.org/lookup/doi/10.1126/science.1075762
- Hucho F, Buchner K Signal Transduction and Protein Kinases: the Long Way from the Plasma Membrane into the Nucleus. Naturwissenschaften [Internet]. 1997;84:281–290. [cited 2021 Apr 20]. Available from: http://link.springer.com/10.1007/s001140050396
- Edel Y, Sagy I, Pokroy-Shapira E, et al. A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. The Israel Medical Association journal : IMAJ [Internet]. 2020;22:154–159. [cited 2021 Apr 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32147979
- Santin G, MMM DS, Villarreal VA, et al. Home storage of biological medications administered to patients with rheumatic diseases. Advances in Rheumatology [Internet]. 2020;60:30.Available from: https://advancesinrheumatology.biomedcentral.com/articles/10.1186/s42358-020-00131-x
- Smolen JS, RBM L, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases [Internet]. 2020;79:annrheumdis-2019-216655. [cited 2021 Apr 20]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-216655
- Stolshek BS, Wade S, Mutebi A, et al. Two-year adherence and costs for biologic therapy for rheumatoid arthritis. Am J Managed Care. 2018;24:SP315–SP321. Internet]. [cited 2021 Apr 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30020744
- Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460.
- Genovese MC, Kremer J, Zamani O, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. New Eng J Med[Internet]. 2016;374:1243–1252. [cited 2021 Apr 20]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1507247
- Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. Internet]. 2018;391:2513–2524. [cited 2021 Apr 20]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618311164
- Takeuchi T, Matsubara T, Atsumi T, et al. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: subgroup analyses of a global phase 3 study (FINCH 2). Mod Rheumatol. 2021;1–16. Internet. doi:https://doi.org/10.1080/14397595.2020.1859675
- Gu NY, Huang XY, Fox KM, et al. Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits. 2010;2:351–359.
- Wehler E, Boytsov N, Nicolay C, et al. A budget impact and cost per additional responder analysis for baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to tumor necrosis factor inhibitors in the USA. PharmacoEconomics. [Internet]. 2020;38:39–56. [cited 2021 Apr 20]. Available from: http://link.springer.com/10.1007/s40273-019-00829-x
- Benjamin Chastek, MS; Stuart D. Segal, MD; R. Peter Bonafede, MD; Crystal Watson, MS; Laura Becker, MS; Sandeep Chaudhari, MS; David J. Harrison, PhD; and Shravanthi R. Gandra, PhD M, ABST. Comparative effectiveness analysis of tnf blockers in rheumatoid arthritis (RA) patients in a real-world setting. Value in Health [Internet]. 2011;14:A1–A2. [cited 2021 Apr 20]. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L70490454%5Cnhttp://gerion.greendata.es:443/sfxlcl3?sid=EMBASE&=10983015&id=doi:&atitle=Comparative+effectiveness+analysis+of+tnf+blockers+in+rheumatoid+arthritis+%28RA%29+patien
- McInnes IB, Buckley CD, Isaacs JD, Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nat Rev Rheumatol. Internet]. 2016;12:63–68. [cited 2021 Apr 20]. Available from: http://www.nature.com/articles/nrrheum.2015.171
- Nyhoff LE, Barron BL, Johnson EM et al., Bruton’s Tyrosine kinase deficiency inhibits autoimmune arthritis in mice but fails to block immune complex-mediated inflammatory arthritis. Arthritis Rheumatol Internet]. 2016;68:1856–1868. Available from. ;(8):
- Whyburn LR, Halcomb KE, Contreras CM, et al. Reduced dosage of bruton’s tyrosine kinase uncouples b cell hyperresponsiveness from autoimmunity in lyn −/− mice. J Immunol. [Internet]. 2003;171:1850–1858. Available from: http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.171.4.1850
- Crofford LJ, Nyhoff LE, Sheehan JH, et al. The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol. [Internet]. 2016;12:763–773. Available from: http://www.tandfonline.com/doi/full/10.1586/1744666X.2016.1152888.
- Sada K, Takano T, Yanagi S, et al. Structure and function of syk protein-tyrosine kinase. J Biochem. [Internet]. 2001;130:177–186. Available from: https://academic.oup.com/jb/article-lookup/doi/10.1093/oxfordjournals.jbchem.a002970.
- Scott IC, Scott DL, Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? Drugs. [Internet]. 2014;74:4. Available from: 415–422. http://link.springer.com/10.1007/s40265-014-0193-9
- Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. [Internet]. 2000;21:148–154. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167569999015741.
- Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124(3):244–257.
- Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16(1):293–322.
- Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
- Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatol (United Kingdom). 2019;58(Supplement_1):i4–i16.
- PH S, AJ K, Ma J, et al., Spebrutinib (CC-292) affects markers of b cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study. Rheumatol Ther. 2020;7(1): 101–119.
- DT F, JJ A, Boers M et al., American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheumatism [Internet]. 1995;38:727–735.
- van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator–controlled trial. Arthritis Rheumatol. Internet]. 2020;72:1607–1620. : https://onlinelibrary.wiley.com/doi/10.1002/art.41384.
- Fleischmann R, Schiff M, van der Heijde D et al., Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol [Internet]. 2017;69:506–517.
- Eun Bong Lee, M.D., Roy Fleischmann, M.D., Stephen Hall, M.D., Bethanie Wilkinson, Ph.D., John D. Bradley, M.D., David Gruben PhD, Tamas Koncz, M.D., Sriram Krishnaswami, Ph.D., Gene V. Wallenstein, Ph.D., Chuanbo Zang, Ph.D., Samuel H. Zwillich, M.D., and Ronald F. van Vollenhoven, M.D. for the OSI. Tofacitinib versus Methotrexate in Rheumatoid Arthritis: Kommentar. The new engl and journal of medicine original. 2014;21:157.
- Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320–1332. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-215163
- Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. [Internet]. 2021;1–11. https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-219214
- Fleischmann R, AL P, Song I, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase double‐blind, randomized controlled trial. Arthritis Rheumatol [Internet]. 2019;71:1788–1800. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41032
- Yang Y, Li X-F, Zhang X, et al. Efficacy and safety of baricitinib in chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE. Rheumatol Ther. 2020;7(4):851–866.
- Fleischmann R, Kremer J, Cush J, et al. Placebo-Controlled Trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. Internet]. 2012;367:495–507. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1109071.
- Kremer JM, Emery P, Camp HS et al., A phase iib study of abt-494, a selective jak-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti–tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68:2867–2877.
- Genovese MC, Kremer JM, Kartman CE, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology. [Internet]. 2018;57:900–908. Available from: https://academic.oup.com/rheumatology/article/57/5/900/4837139.
- Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med [Internet]. 2017;376(7):652–662. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1608345
- Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet Internet]. 2017;390 10093:457–468. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673617316185
- van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheumatism. 2013;65(3):559–570. [Internet]. Available from: http://doi.wiley.com/10.1002/art.37816
- Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. N Engl J Med. 2014;370(25):2377–2386. Internet]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1310476
- Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–2311. Internet.
- Joel Kremer, MD; Zhan-Guo Li, MD, PhD; Stephen Hall, MD; Roy Fleischmann, MD; Mark Genovese, MD; Emilio Martin-Mola, MD P, John D. Isaacs, PhD; David Gruben, PhD; Gene Wallenstein, PhD; Sriram Krishnaswami, PhD; Samuel H. Zwillich, MD; Tamas Koncz M, Richard Riese, MD, PhD; and John Bradley M. Original research tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis. Ann Intern Med. 2013;159(253–26):253. Internet]. Available from: http://annals.org/article.aspx?doi=10.7326/0003-4819-159-4-201308200-00006.
- Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320–1332.
- Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305–1319. Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-215164
- Genovese MC, Greenwald MW, Gutierrez-Ureña SR, et al. Two-year safety and effectiveness of peficitinib in moderate-to-severe rheumatoid arthritis: a phase iib, open-label extension study. Rheumatol Ther. 2019;6(4):503–520.
- Kivitz AJ, Gutierrez-Ureña SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–719. [Internet]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.39955
- Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK Inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):932–942. Internet]. ;:. Available from. : https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40054
- Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057–1064. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-208279
- Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective jak-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase iia trials. Arthritis Rheumatol. 2017;69(10):1949–1959.
- Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76(6):998–1008. [Internet]: Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-210104
- Genovese MC, Yang F, Østergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis. 2016;75(11):1979–1983. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-208901
- Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Revmatologiia. 2020;59:3303–3313. [Internet]. Available from: https://academic.oup.com/rheumatology/article/59/11/3303/5819165
- Burmester GR, Kremer JM, van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. Internet.
- Mark C. Genovese1, Joel M. Kremer2, Cynthia Kartman3, Douglas E. Schlichting3, Li Xie3, Tara Carmack4, William L. Macias3 and Josef S. Smolen5, 1Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, 2Center for Rheumatology, Albany, A. Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol Internet]. 2018;67:1–4.
- Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95.
- Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016;68(12):2857–2866.
- Fleischmann R, Takeuchi T, Schiff M, et al. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care Res [Internet]. 2020;72:1112–1121. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.24007
- Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. [Internet]. 2016;43:504–511. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.150613.
- Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2014-206478
- Combe B, Balsa A, Sarzi-Puttini P, et al. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019;78(8):1135–1138. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-214261
- van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. N Engl J Med. 2012;367(6):508–519. [Internet]. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1112072
- Conaghan PG, Østergaard M, Bowes MA, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati. Ann Rheum Dis. 2016;75(6):1024–1033.
- Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheumatism. 2012;64(3):617–629. Internet.
- Tanaka Y, Takeuchi T, Yamanaka H, et al. Effi cacy and safety of tofacitinib as monotherapy in japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25(4):514–521. [Internet]. Available from: http://www.tandfonline.com/doi/full/10.3109/14397595.2014.995875
- Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis [Internet]. 2017;76:1009–1019. Available from https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-2101056101136/annrheumdis–2016–210105
- Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and Efficacy of Filgotinib: up to 4-Year Results From an Open-Label Extension Study of Phase 2 Rheumatoid Arthritis Programs. J Rheumatol. 2021;48(8):1230–1238. [Internet]. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.201183
- Genovese MC, Greenwald MW, Gutierrez-Ureña SR, et al. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: a Phase IIb, Open-Label Extension Study. Rheumatol Ther. 2019;6(4):503–520. [Internet]. Available from: http://link.springer.com/10.1007/s40744-019-00167-6
- Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95. [Internet]. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-210094
- Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75(7):1293–1301. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2014-207178
- Kjelgaard-Petersen CF, Platt A, Braddock M, et al. Translational biomarkers and ex vivo models of joint tissues as a tool for drug development in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(9):1419–1428.
- Michael E. Weinblatt, M.D., Arthur Kavanaugh, M.D., Mark C. Genovese, M.D., Theresa K. Musser BA, Elliott B. Grossbard, M.D., and Daniel B. Magilavy MD. An oral spleen tyrosine kinase (syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;2006:687–696.
- Genovese MC, van der Heijde DM, Keystone EC, et al. A phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist. J Rheumatol. 2014;41(11):2120–2128. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.140238
- Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015;74(12):2123–2129. Internet]. Available from. : https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2014-205361
- Tanaka Y, Millson D, Iwata S, et al. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology. 2020;1–12. Available from https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaa732/6012959
- Weinblatt ME, Kavanaugh A, Genovese MC, et al. An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. N Engl J Med. 2010;363(14):1303–1312. [Internet]. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1000500
- McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227–1239. [Internet]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2022516
- Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312–320.
- Lee YH, Song GG. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol [Internet]. 2020;79 6:590–603. Available from http://link.springer.com/10.1007/s00393-019-00733-x
- Miyazaki Y, Nakano K, Nakayamada S, et al. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Internet]. 2021;annrheumdis-2020-219699. Available from. Ann Rheum Dis. ;80(Suppl 1):329.1–329. https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-219699
- Weinblatt ME, Kavanaugh A, Genovese MC, et al. An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis. New England Journal of Medicine [Internet]. 2010;363:1303–1312. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1000500.